MAPT and Alzheimer disease: In addition, in a real‐world clinical setting, a lot of patients can show early symptoms overlapping with early AD, but caused by different underlying non‐AD neuropathological processes, as confirmed by amyloid and tau biomarker negativity, many of which do not still have robust and specific in vivo biomarkers.5